We are pleased to share that Cellis was awarded with the MACOV Transition Grant funded by the European Innovation Council (EIC).
The project MACOV started in November 2022 and aims to develop an innovative, allogeneic, off-the-shelf macrophage-based therapy for platinum-resistant ovarian cancer.
This is a ground-breaking, first in class therapy that shows very high efficacy in multiple solid tumors of unmet medical need.
Read more on EIC Transition Grants website.
